MTTP I128T — A Missense Variant That Reshapes Lipid Export from the Liver
Your liver is a lipid logistics hub. Every gram of fat synthesized from excess
carbohydrate, every fatty acid rescued from circulation, every dietary fat
re-exported after absorption — all of it leaves the liver packaged into
VLDL particles11 VLDL particles
Very-low-density lipoprotein: triglyceride-rich particles
assembled in the liver and secreted into blood, where they deliver fat to
peripheral tissues. The enzyme
responsible for loading triglycerides into those particles is
MTTP — microsomal triglyceride transfer protein22 MTTP — microsomal triglyceride transfer protein
MTTP transfers
triglycerides, phospholipids, and cholesteryl esters onto nascent apolipoprotein
B during VLDL assembly in the liver and chylomicron assembly in the intestine.
Without functional MTTP, VLDL cannot be assembled, triglycerides accumulate in
hepatocytes, and plasma lipid levels fall sharply — the phenotype of
abetalipoproteinemia, a rare recessive disorder caused by null MTTP mutations.
The I128T variant (rs3816873) substitutes isoleucine for threonine at position 128 of the MTTP protein. It is common — the Thr128 (C) allele occurs in about 25% of Europeans and 34% of South Asians — yet it was classified as benign for years, its metabolic effects dismissed as too modest to matter. That view has changed.
The Mechanism
Isoleucine at position 12833 Isoleucine at position 128
A nonpolar, branched-chain amino acid embedded in
the hydrophobic core of the MTTP N-terminal domain
sits in a region of MTTP critical for its lipid-transfer scaffold. The
Ile→Thr substitution44 Ile→Thr substitution
Threonine is polar and hydroxyl-bearing; replacing a
hydrophobic residue with a polar one at this position likely alters
the protein's local conformational dynamics
changes the physicochemical character of this site — polar threonine where
non-polar isoleucine once held structure. This does not abolish MTTP activity
(as null mutations do in abetalipoproteinemia). A 2023 study in 489,000+ participants concluded the I128T variant
is "neither a classic loss nor gain of function allele," pointing to a more
nuanced alteration of MTP lipid-transfer dynamics that simultaneously reduces
hepatic fat retention and plasma lipid levels.
The Evidence
The strongest evidence comes from a large biobank study55 large biobank study
Schneider et al. 2023,
Penn Medicine Biobank (n=37,960) and UK Biobank (n=451,444), examining 24 MTTP
missense variants. Carriers of the
Thr128 (C) allele showed reduced hepatic steatosis on imaging, fewer biopsy-proven
steatosis cases, and lower plasma LDL-cholesterol and apoB concentrations
(all p<0.001). The scale of this study makes confounding unlikely.
Smaller studies give a more complex picture. A 2011 Iranian case-control study66 2011 Iranian case-control study
Hashemi et al., 83 NAFLD cases vs. 93 controls, DNA Cell Biol
found the CT genotype had an OR of 2.467 (95% CI 1.253–4.854) for NAFLD — a risk
direction opposite to the biobank data. However, a 2020 meta-analysis of three
case-control studies77 2020 meta-analysis of three
case-control studies
Tan et al., Saudi J Gastroenterol found no
significant overall association (OR 1.23, 95% CI 0.76–2.01, p=0.398), implying
the small-study positive findings likely reflect population stratification or
underpowering. In the context of viral hepatitis, the variant showed a strong
interaction effect: Prata et al. 202288 Prata et al. 2022
236 chronic hepatitis C patients, Clinics
São Paulo found the I128T allele
combined with HCV genotype 3 produced an 8.5-fold elevated steatosis risk —
a clinically important gene-virus interaction.
For Korean patients with alcoholic liver disease, the wild-type Ile128 (T allele)99 wild-type Ile128 (T allele)
Jun et al. 2009, Eur J Gastroenterol Hepatol
was more prevalent in those with fatty liver, and I/I carriers showed significantly
elevated ALT — consistent with the C allele (Thr128) being protective in the
context of alcohol-related hepatic stress.
Practical Actions
The Thr128 C allele is associated with reduced hepatic fat accumulation at population scale.
Wild-type T;T homozygotes carry the ancestrally common form (Ile128). Their hepatic fat risk is not dramatic but warrants awareness, particularly in the context of alcohol use.
Heterozygous C;T carriers fall between these two extremes.
Interactions
The most clinically documented interaction is with HCV genotype 3 infection: I128T carriers with this viral strain show dramatically elevated hepatic steatosis risk (OR ~8.5), suggesting the variant's effect on MTTP function is exacerbated by HCV-driven lipid dysregulation. This is a gene-virus interaction rather than a gene-gene interaction in the traditional sense.
For gene-gene interactions, MTTP function interacts with APOE genotype (which governs apolipoprotein B receptor-mediated clearance), PCSK9 variants (which modulate LDL receptor density), and PNPLA3 rs738409 (a well-replicated NAFLD risk variant in a different pathway — hepatic triglyceride hydrolysis).